International Process Plants (IPP), a buyer and supplier of used, new, and refurbished process plants and equipment, is positioning its Humber Industrials Ltd. integrated small molecule API manufacturing platform to the pharmaceutical, CDMO, and fine chemical market. The company aims to provide a capital-light opportunity for companies seeking capacity without the traditional capital burden of acquiring or leasing an entire manufacturing site upfront.

At IPP’s Grimsby, UK site, qualified companies can utilize one or more of three established pharmaceutical manufacturing plants on the campus under a flexible commercial structure designed to allow growth into capacity for new projects, expansion, or reshoring over time without the burden of upfront acquisition. Rather than requiring immediate large-scale capital commitment, IPP aims to support occupancy and phased production through a step-up lease model tied to actual utilization and operating ramp-up.

This structure aims to provide pharma, CDMO, and fine chemical manufacturers the ability to establish or expand API and raw/key starting materials capacity on a world-class site with minimal upfront CAPEX, while preserving capital for process development, regulatory work, working capital, validation, and commercial growth.

For pharmaceutical groups evaluating supply chain resilience, Western manufacturing optionality, or faster access to GMP-capable infrastructure, the Grimsby site offers strategic proximity to the broader European market, while also providing a platform for transatlantic supply into the U.S. 

“This is not a conventional lease or acquisition opportunity,” said Ross Gale, Vice President of International Process Plants. “It is a truly unique platform for pharmaceutical and related manufacturers that need credible, commercial scale production capability without tying up capital in bricks and mortar before the business is operating. We are prepared to work with the right counterparties to create a practical pathway into one, two, or all three plants at Grimsby without the burden of the upfront capital requirement of building or buying capacity.”

IPP is inviting discussions with qualified pharmaceutical, CDMO, fine chemical, and strategic manufacturing counterparties interested in occupying and growing into available capacity at the Grimsby site under creative and commercially aligned structures.